Ixazomib - Takeda Oncology

Drug Profile

Ixazomib - Takeda Oncology

Alternative Names: Ixazomib citrate; MLN-2238; MLN-9708; NINLARO

Latest Information Update: 09 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals; University of California, San Diego
  • Developer Celgene Corporation; Helsinki University Central Hospital; HOVON Foundation; Massachusetts General Hospital; National Cancer Institute (USA); Northside Hospital; Northwestern University; Takeda Oncology; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Organic boron compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase III Amyloid light-chain amyloidosis
  • Phase II Acute myeloid leukaemia; Amyloidosis; Follicular lymphoma; Haematological malignancies; Lymphoma; Myelodysplastic syndromes; Waldenstrom's macroglobulinaemia
  • Phase I/II Bladder cancer; Graft-versus-host disease; HIV infections; Mantle-cell lymphoma
  • Phase I Non-small cell lung cancer; Pancreatic cancer
  • No development reported Lupus nephritis; Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Solid tumours

Most Recent Events

  • 31 Oct 2018 Phase-I clinical trials in Multiple myeloma (Newly diagnosed, Maintenance therapy) in China (PO)
  • 01 Oct 2018 University of California, Celgene, Takeda and Janssen initiates enrolment in a phase II trial for Multiple Myeloma (Combination therapy, Second-line therapy or greater) in USA (NCT03590652)
  • 08 Aug 2018 Takeda plans the phase II IDEALL trial for Multiple myeloma (combination therapy, First-line therapy) in May 2019 (NCT03608501)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top